{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-020707","form_type":"8-K","ticker":"ELTP","cik":"0001053369","company_name":"ELITE PHARMACEUTICALS INC /NV/","filed_at":"2024-05-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.060028+00:00","generated_at":"2026-06-01T12:09:04.270844+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Elite Pharma receives FDA approval for generic Methotrexate; market $64.3M annual sales","bullets":["FDA approved ANDA for generic Methotrexate Sodium 2.5 mg tablets on May 16, 2024.","Product will be marketed under Elite Laboratories, Inc. label.","IQVIA reports $64.3 million in annual U.S. generic market sales (12 months ending Mar 2024)."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-020707","json":"https://secwatch.observer/filing/0001493152-24-020707.json","markdown":"https://secwatch.observer/filing/0001493152-24-020707.md","text":"https://secwatch.observer/filing/0001493152-24-020707.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053369/000149315224020707/0001493152-24-020707-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053369/000149315224020707/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T12:09:04.270844+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}